Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation

European Journal of Medicinal Chemistry

Volumn 62, Issue , 2013, Pages 379-394

  Nuti, Elisa ^a   Santamaria, Salvatore ^b,c   Casalini, Francesca ^a   Yamamoto, Kazuhiro ^c   Marinelli, Luciana ^d   La Pietra, Valeria ^d   Novellino, Ettore ^d   Orlandini, Elisabetta ^a   Nencetti, Susanna ^a   Marini, Anna Maria ^a   Salerno, Silvia ^a   Taliani, Sabrina ^a   Da Settimo, Federico ^a   Nagase, Hideaki ^b,c   Rossello, Armando ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ADAMTS 4; ADAMTS 5; Aggrecanase inhibitors; Arylsulfonamido based hydroxamates; Osteoarthritis

Indexed keywords

2 (4 BUTOXYPHENYLSULFONAMIDO) N HYDROXYACETAMIDE; 2 [4 (2 CHLORO 4 FLUOROBENZYLOXY)PHENYLSULFONAMIDO] N HYDROXYACETAMIDE; 2 [4 (BENZYLOXY) N ISOBUTYLPHENYLSULFONAMIDO] N HYDROXYACETAMIDE; 2 [4 (BENZYLOXY) N ISOPROPOXYPHENYLSULFONAMIDO] N HYDROXYACETAMIDE; 2 [4 (BENZYLOXY)PHENYLSULFONAMIDO] N HYDROXYACETAMIDE; 2 [4 BROMO 2 (TRIFLUOROMETHOXY)PHENYLSULFONAMIDO] N HYDROXYACETAMIDE; AGGRECANASE; AGGRECANASE 1; AGGRECANASE 2; COLLAGENASE 3; GLYCOSAMINOGLYCAN; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; N HYDROXY 2 (4 PHENOXYPHENYLSULFONAMIDO)ACETAMIDE; N HYDROXY 2 (6 PHENOXYPYRIDINE 3 SULFONAMIDO)ACETAMIDE; N HYDROXY 2 [4 (6 METHYLPYRAZIN 2 YLOXY)PHENYLSULFONAMIDO]ACETAMIDE; N HYDROXY 2 [4 (PHENOXYMETHYL)PHENYLSULFONAMIDO]ACETAMIDE; N HYDROXY 2 [4 (PYRROLIDIN 1 YLSULFONYL)PHENYLSULFONAMIDO]ACETAMIDE; N HYDROXY 3 (4 PHENOXYPHENYLSULFONAMIDO)PROPANAMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; OSTEOARTHRITIS; PROTEIN DEGRADATION;

ADAM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSTEOARTHRITIS; PROCOLLAGEN N-ENDOPEPTIDASE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84873032924     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.12.058     Document Type: Article

References (58)

1. C.G. Helmick, D.T. Felson, R.C. Lawrence, S. Gabriel, R. Hirsch, C. Kent Kwoh, M.H. Liang, H. Maradit Kremers, M.D. Mayes, P.A. Merkel, S.R. Pillemer, J.D. Reveille, and J.H. Stone Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I Arthritis Rheum. 58 2008 15 25
2. D.P. Symmons, C.D. Mathers, B.P. fleger, The global burden of osteoarthritis in the year 2000, GBD 2000 Working Paper, World Health Organisation, Geneva, http://www.who.int/healthinfo/statistics/bod- osteoarthritis.pdf.
3. M. Fajardo, and P.E. Di Cesare Disease-modifying therapies for osteoarthritis: current status Drugs Aging 22 2005 141 161
4. B.M. Vertel, and A. Ratcliffe Aggrecan R.V. Iozzo, Proteoglycans: Structure, Biology and Molecular Interactions 2000 Marcel Dekker New York 343 377
5. M.J. Pond, and G. Nuki Experimentally induced osteoarthritis in the dog Ann. Rheum. Dis. 32 1973 387 388
6. M.D. Tortorella, T.C. Burn, M.A. Pratta, I. Abbaszade, J.M. Hollis, R. Liu, S.A. Rosenfeld, R.A. Copeland, C.P. Decicco, R. Wynn, A. Rockwell, F. Yang, J.L. Duke, K. Solomon, H. George, R. Bruckner, H. Nagase, Y. Itoh, D.M. Ellis, H. Ross, B.H. Wiswall, K. Murphy, M.C. Hillman Jr., G.F. Hollis, R.C. Newton, R.L. Magolda, J.M. Trzaskos, and E.C. Arner Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins Science 284 1999 1664 1666
7. J.D. Sandy, P.J. Neame, R.E. Boynton, and C.R. Flannery Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain J. Biol. Chem. 266 1991 8683 8685
8. C.B. Little, C.T. Meeker, S.B. Golub, K.E. Lawlor, P.J. Farmer, S.M. Smith, and A.J. Fosang Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair J. Clin. Invest. 117 2007 1627 1636
9. L.S. Lohmander, P.J. Neame, and J.D. Sandy The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis Arthritis Rheum. 36 1993 1214 1222
10. M.D. Tortorella, A.M. Malfait, C. Deccico, and E. Arner The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation Osteoarthr. Cartil. 9 2001 539 552
11. C. Gendron, M. Kashiwagi, N.H. Lim, J.J. Enghild, I.B. Thogersen, C. Hughes, B. Caterson, and H. Nagase Proteolytic activities of human ADAMTS-5. Comparative studies with ADAMTS-4 J. Biol. Chem. 282 2007 18294 18306
12. S.S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H.L. Ma, C.R. Flannery, D. Peluso, Z. Yang, M.K. Majumdar, and E.A. Morris Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis Nature 434 2005 644 648
13. H. Stanton, F.M. Rogerson, C.J. East, S.B. Golub, K.E. Lawlor, C.T. Meeker, C.B. Little, K. Last, P.J. Farmer, I.K. Campbell, A.M. Fourie, and A.J. Fosang ADAMTS-5 is the major aggrecanase in mouse cartilage in vivo and in vitro Nature 434 2005 648 652
14. A.M. Malfait, J. Ritchie, A.S. Gil, J.S. Austin, J. Hartke, W. Qin, M.D. Tortorella, and J.S. Mogil ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization Osteoarthr. Cartil. 18 2010 572 580
15. J. Li, W. Anemaet, M.A. Diaz, S. Buchanan, M. Tortorella, A.M. Malfait, K. Mikecz, J.D. Sandy, and A. Plaas Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models J. Orthop. Res. 29 2011 516 522
16. S.S. Glasson, R. Askew, B. Sheppard, B.A. Carito, T. Blanchet, H.L. Ma, C.R. Flannery, K. Kanki, E. Wang, D. Peluso, Z. Yang, M.K. Majumdar, and E.A. Morris Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice Arthritis Rheum. 50 2004 2547 2558
17. C. De Savi, A. Pape, Y. Sawyer, D. Milne, C. Davies, J.G. Cumming, A. Ting, S. Lamont, P.D. Smith, J. Tart, K. Page, and P. Moore Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 21 2011 3301 3306
18. C. De Savi, A. Pape, J.G. Cumming, A. Ting, P.D. Smith, J.N. Burrows, M. Mills, C. Davies, S. Lamont, D. Milne, C. Cook, P. Moore, Y. Sawyer, and S. Gerhardt The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 21 2011 1376 1381
19. R.J. Cherney, R. Mo, D.T. Meyer, L. Wang, W. Yao, Z.R. Wasserman, R.Q. Liu, M.B. Covington, M.D. Tortorella, E.C. Arner, M. Qian, D.D. Christ, J.M. Trzaskos, R.C. Newton, R.L. Magolda, and C.P. Decicco Potent and selective aggrecanase inhibitors containing cyclic P1 substituents Bioorg. Med. Chem. Lett. 13 2003 1297 1300
20. W. Yao, Z.R. Wasserman, M. Chao, G. Reddy, E. Shi, R.Q. Liu, M.B. Covington, E.C. Arner, M.A. Pratta, M. Tortorella, R.L. Magolda, R. Newton, M. Qian, M.D. Ribadeneira, D. Christ, R.R. Wexler, and C.P. Decicco Design and synthesis of a series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2- hydroxy-2,3-dihydro-1Hinden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors J. Med. Chem. 44 2001 3347 3350
21. M.C. Noe, V. Natarajan, S.L. Snow, P.G. Mitchell, L. Lopresti-Morrow, L.M. Reeves, S.A. Yocum, T.J. Carty, J.A. Barberia, F.J. Sweeney, J.L. Liras, M. Vaughn, J.R. Hardink, J.M. Hawkins, and C. Tokar Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13 Bioorg. Med. Chem. Lett. 15 2005 2808 2811
22. A. Cappelli, C. Nannicini, S. Valenti, G. Giuliani, M. Anzini, M. Mennuni, A. Giordani, G. Caselli, L.P. Stasi, F. Makovec, G. Giorgi, and S. Vomero Design, synthesis, and preliminary biological evaluation of pyrrolo[3,4-c]quinolin-1-one and oxoisoindoline derivatives as aggrecanase inhibitors Chem. Med. Chem. 5 2010 739 748
23. M.G. Bursavich, A.M. Gilbert, S. Lombardi, K.E. Georgiadis, E. Reifenberg, C.R. Flannery, and E.A. Morris Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2) Bioorg. Med. Chem. Lett. 17 2007 1185 1188
24. A.M. Gilbert, M.G. Bursavich, S. Lombardi, K.E. Georgiadis, E. Reifenberg, C.R. Flannery, and E.A. Morris 5-((1H-pyrazol-4-yl)methylene)-2- thioxothiazolidin-4-one inhibitors of ADAMTS-5 Bioorg. Med. Chem. Lett. 17 2007 1189 1192
25. A.M. Gilbert, M.G. Bursavich, S. Lombardi, K.E. Georgiadis, E. Reifenberg, C.R. Flannery, and E.A. Morris N-((8-Hydroxy-5-substituted-quinolin- 7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (aggrecanase-2) Bioorg. Med. Chem. Lett. 18 2008 6454 6457
26. V. La Pietra, L. Marinelli, S. Cosconati, F.S. Di Leva, E. Nuti, S. Santamaria, I. Pugliesi, M. Morelli, F. Casalini, A. Rossello, C. La Motta, S. Taliani, R. Visse, H. Nagase, F. Da Settimo, and E. Novellino Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization Eur. J. Med. Chem. 47 2012 143 152
27. M. Shiozaki, K. Maeda, T. Miura, M. Kotoku, T. Yamasaki, I. Matsuda, K. Aoki, K. Yasue, H. Imai, M. Ubukata, A. Suma, M. Yokota, T. Hotta, M. Tanaka, Y. Hase, J. Haas, A.M. Fryer, E.R. Laird, N.M. Littmann, S.W. Andrews, J.A. Josey, T. Mimura, Y. Shinozaki, H. Yoshiuchi, and T. Inaba Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors J. Med. Chem. 54 2011 2839 2863
28. E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli, N.H. Lim, R. Visse, H. Nagase, and A. Rossello N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis J. Med. Chem. 52 2009 4757 4773
29. S. Santamaria, E. Nuti, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino, and A. Rossello N-O-Isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors Biochem. Pharmacol. 84 2012 813 820
30. J.T. Peterson The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors Cardiovasc. Res. 69 2006 677 687
31. D.P. Becker, T.E. Barta, L.J. Bedell, T.L. Boehm, B.R. Bond, J. Carroll, C.P. Carron, G.A. Decrescenzo, A.M. Easton, J.N. Freskos, C.L. Funckes-Shippy, M. Heron, S. Hockerman, C.P. Howard, J.R. Kiefer, M.H. Li, K.J. Mathis, J.J. McDonald, P.P. Mehta, G.E. Munie, T. Sunyer, C.A. Swearingen, C.I. Villamil, D. Welsch, J.M. Williams, Y. Yu, and J. Yao Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease J. Med. Chem. 53 2010 6653 6680
32. A. Rossello, E. Nuti, E. Orlandini, P. Carelli, S. Rapposelli, M. Macchia, F. Minutolo, L. Carbonaro, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) Bioorg. Med. Chem. 12 2004 2441 2450
33. E. Nuti, E. Orlandini, S. Nencetti, A. Rossello, A. Innocenti, A. Scozzafava, and C.T. Supuran Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates Bioorg. Med. Chem. 15 2007 2298 2311
34. C. Nieto-Oberhuber, S. Lòpez, M.P. Muñoz, E. Jiménez-Nùñez, E. Buñuel, D.J. Càrdenas, and A.M. Echavarren Gold(I)-catalyzed intramolecular cyclopropanation of dienynes Chem. Eur. J. 12 2006 1694 1702
35. H.S. Shieh, K.J. Mathis, J.M. Williams, R.L. Hills, J.F. Wiese, T.E. Benson, J.R. Kiefer, M.H. Marino, J.N. Carroll, J.W. Leone, A.M. Malfait, E.C. Arner, M.D. Tortorella, and A. Tomasselli High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2) Biol. Chem. 283 2008 1501 1507
36. E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, M. Fabbi, S. Ferrini, L. Marinelli, V. La Pietra, V. Limongelli, E. Novellino, G. Cercignani, E. Orlandini, S. Nencetti, and A. Rossello Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models J. Med. Chem. 53 2010 2622 2635
37. R.E. Galardy, and Galardin Drugs Future 18 1993 1109 1111
38. A.R. Johnson, A.G. Pavlovsky, D.F. Ortwine, F. Prior, C.F. Man, D.A. Bornemeier, C.A. Banotai, W.T. Mueller, P. McConnell, C. Yan, V. Baragi, C. Lesch, W.H. Roark, M. Wilson, K. Datta, R. Guzman, H.K. Han, and R.D. Dyer Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects J. Biol. Chem. 282 2007 27781 27791
39. M. Neya, H. Yamazaki, K. Sato, N. Yoshida, Y. Imamura, H. Setoi, Preparation of arylamido-substituted (hetero)cycloalkylacetamides as MMP and TNF-α inhibitors, WO 2000063165 A1 20001026.
40. L.A. Reiter, R.P. Robinson, K.F. McClure, C.S. Jones, M.R. Reese, P.G. Mitchell, I.G. Otterness, M.L. Bliven, J. Liras, S.R. Cortina, K.M. Donahue, J.D. Eskra, R.J. Griffiths, M.E. Lame, A. Lopez-Anaya, G.J. Martinelli, S.M. McGahee, S.A. Yocum, L.L. Lopresti-Morrow, L.M. Tobiassen, and M.L. Vaughn-Bowser Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1 Bioorg. Med. Chem. Lett. 14 2004 3389 3395
41. M.C. Noe, V. Natarajan, S.L. Snow, L.A. Wolf-Gouveia, P.G. Mitchell, L. Lopresti-Morrow, L.M. Reeves, S.A. Yocum, I. Otterness, M.A. Bliven, T.J. Carty, J.T. Barberia, F.J. Sweeney, J.L. Liras, and M. Vaughn Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13 Bioorg. Med. Chem. Lett. 15 2005 3385 3388
42. E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria, S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, N. D'Amelio, A. Maiocchi, F. Uggeri, and A. Rossello Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent Matrix Metalloproteinase-12 inhibitors J. Med. Chem. 52 2009 6347 6361
43. SoftMax Pro 4.7.1 by Molecular Devices.
44. GraFit version 4 by Erithecus Software.
45. V.C. Hascall, and S.W. Sajdera Protein-polysaccharide complex from bovine nasal cartilage. The function of glycoprotein in the formation of aggregates J. Biol. Chem. 244 1969 2384 2396
46. C.E. Hughes, B. Caterson, A.J. Fosang, P.J. Roughley, and J.S. Mort Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro Biochem. J. 305 1995 799 804
47. R.W. Farndale, D.J. Buttle, and A.J. Barrett Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue Biochim. Biophys. Acta 883 1986 173 177
48. Glide, Version 5.5 2009 Schrödinger, LLC New York, NY
49. Maestro, Version 9.0.211 2009 Schrodinger, L.L.C New York, NY
50. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF chimera e a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612
51. A.W. Schuttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of proteineligand complexes Acta Crystallogr. Sect. D Biol. Crystallogr. 60 2004 1355 1363
52. J.W. Storer, D.J. Giesen, C.J. Cramer, and D.G. Truhlar Class IV charge models: a new semiempirical approach in quantum chemistry J. Comput.-Aided Mol. Des. 9 1995 87 110
53. J.D. Thompson, C.J. Cramer, and D.G. Truhlar Parameterization of charge model 3 for AM1, PM3, BLYP, and B3LYP J. Comput. Chem. 24 2003 1291 1304
54. W.L. Jorgensen, D.S. Maxwell, and J. Tirado-Rives Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 118 1996 11225 11236
55. W.L.B.O.S.S. Jorgensen Version 4.6 2004 Yale University New Haven, CT
56. M. Udier-Blagovic, P. Morales De Tirado, S.A. Pearlman, and W.L. Jorgensen Accuracy of free energies of hydration using CM1 and CM3 atomic charges J. Comput. Chem. 25 2004 1322 1332
57. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
58. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 49 2006 6177 6196